Treatment Strategies for Atopic Dermatitis: Optimizing the Available Therapeutic Options

Seminars in Cutaneous Medicine and Surgery

Volumn 31, Issue 3 SUPPL., 2012, Pages

  Paller, Amy S ^a,e   Simpson, Eric L ^b   Eichenfield, Lawrence F ^c   Ellis, Charles N ^d   Mancini, Anthony J ^a,e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Atopic dermatitis treatment; Bleach baths; Staphylococcus aureus colonization

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; EMOLLIENT AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; TACROLIMUS;

ANTIMICROBIAL THERAPY; ATOPIC DERMATITIS; BATH; BLOOD CELL COUNT; BLOOD PRESSURE MONITORING; DRUG DOSE REDUCTION; DRUG MECHANISM; HUMAN; HYDRATION; HYPERTRICHOSIS; INFECTION; INFECTION PREVENTION; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; LOTION; NEOPLASM; NEPHROTOXICITY; OINTMENT; REVIEW; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; TACHYPHYLAXIS; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; BATHS; COMBINED MODALITY THERAPY; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EMOLLIENTS; HUMANS; PRURITUS; SKIN DISEASES, INFECTIOUS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84866872224     PISSN: 10855629     EISSN: 15580768     Source Type: Journal    
DOI: 10.1016/j.sder.2012.07.004     Document Type: Review

References (38)

1. Krejci-Manwaring J., Tusa M.G., Carroll C., et al. Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007, 56:211-216.
2. Feldman S.R., Camacho F.T., Krejci-Manwaring J., et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007, 57:81-83.
3. Chisolm S.S., Taylor S.L., Balkrishnan R., et al. Written action plans: Potential for improving outcomes in children with atopic dermatitis. J Am Acad Dermatol 2008, 59:677-683.
4. Draelos Z.D. New treatments for restoring impaired epidermal barrier permeability: Skin barrier repair creams. Clin Dermatol 2012, 30:345-348.
5. Aubert-Wastiaux H., Moret L., Le Rhun A., et al. Topical corticosteroid phobia in atopic dermatitis: A study of its nature, origins and frequency. Br J Dermatol 2011, 165:808-814.
6. Paller A., Eichenfield L.F., Leung D.Y.M., et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001, 44:S47-S57.
7. Mandelin J.M., Rubins A., Remitz A., et al. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants: A two-year open-label study. Int J Dermatol 2012, 51:104-110.
8. Bishop M., Vukovic-Wysocki I., Qaqundah P., et al. A 5-year randomized study to investigate the safety of pimecrolimus cream 1% in the treatment of mild-to-moderate atopic dermatitis in infants: Immunologic parameters. J Am Acad Dermatol 2011, 64(2 suppl 1):AB56.
9. Eichenfield L.F., Beck L. Elidel (pimecrolimus) cream 1%: A nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003, 111:1153-1168.
10. Margolis D.J., Hoffstad O., Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007, 214:289-295.
11. Arellano F.M., Arana A., Wentworth C.E., et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol 2009, 123:1111-1116.
12. Arellano F.M., Wentworth C.E., Arana A., et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007, 127:808-816.
13. Ohtsuki M, Ohara H, Santos V, et al: Safety profiles of two large cohort studies of tacrolimus ointment for the treatment of atopic dermatitis: A prospective pediatric longitudinal evaluation study (APPLES) and Japanese long-term safety study (J-LSS). Poster presented at: 22nd World Congress of Dermatology; May 24-29, 2011; Seoul, Korea.
14. Kao J.S., Fluhr J.W., Man M.Q., et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: Inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003, 120:456-464.
15. Cork M.J., Varghese J., Hadcraft J., et al. Differences in the effect of topical corticosteroids and calcineurin inhibitors on the skin barrier: Implications for therapy. J Invest Dermatol 2007, 127:S45.
16. Cork MJ, Varghese J, Sultan A, et al: Therapeutic implications of the differential effects of topical corticosteroids and calcineurin inhibitors on the skin barrier. Poster presented at: 5th George Rajka International Symposium on Atopic Dermatitis (ISAD); May 11-13, 2008; Kyoto, Japan.
17. Cork M.J., Danby S.G., Vasilopoulos Y., et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009, 129:1892-1908.
18. Paller A.S., Eichenfield L.F., Kirsner R.S., et al. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: A new paradigm for use. Pediatrics 2008, 122:e1210-e1218.
19. Hanifin J., Gupta A.K., Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002, 147:528-537.
20. Huang J.T., Abrams M., Tlougan B., et al. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 2009, 123:e808-e814.
21. Breneman D., Fleischer A.B., Abramovits W., et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol 2008, 58:990-999.
22. Thaci D., Chambers C., Sidhu M., et al. Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: Clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol 2010, 24:1040-1046.
23. Carr J., Akram M., Sultan A., et al. Contamination of emollient creams and ointments with Staphylococcus aureus in children with atopic dermatitis. Dermatitis 2008, 19:282.
24. Bonness S., Szekat C., Novak N., et al. Pulsed-field gel electrophoresis of Staphylococcus aureus isolates from atopic patients revealing presence of similar strains in isolates from children and their parents. J Clin Microbiol 2008, 46:456-461.
25. Mailhol C., Lauwers-Cances V., Rancé F., et al. Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: A study in 641 children. Allergy 2009, 64:801-806.
26. Beattie P.E., Green C., Lowe G., et al. Which children should we patch test?. Clin Exp Dermatol 2007, 32:6-11.
27. Schmitt J., Schmitt N., Meurer M. Cyclosporin in the treatment of patients with atopic eczema: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007, 21:606-619.
28. Harper J.I., Ahmed I., Barclay G., et al. Cyclosporin for severe childhood atopic dermatitis: Short course versus continuous therapy. Br J Dermatol 2000, 142:52-58.
29. Harper J.I., Berth-Jones J., Camp R.D., et al. Cyclosporin for atopic dermatitis in children. Dermatology 2001, 203:3-6.
30. Hon K.L., Ching G.K., Leung T.F., et al. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatolog Treat 2009, 20:141-145.
31. Waxweiler W.T., Agans R., Morrell D.S. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol 2011, 28:689-694.
32. Murphy L.A., Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol 2002, 147:308-315.
33. Heller M., Shin H.T., Orlow S.J., et al. Mycophenolate mofetil for severe childhood atopic dermatitis: Experience in 14 patients. Br J Dermatol 2007, 157:127-132.
34. Weatherhead S.C., Wahie S., Reynolds N.J., et al. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 2007, 156:346-351.
35. Clayton T.H., Clark S.M., Turner D., et al. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol 2007, 32:28-33.
36. Dabade T.S., Davis D.M., Wetter D.A., et al. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: Experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol 2012, 67:100-106.
37. Devillers A.C., Oranje A.P. Wet-wrap treatment in children with atopic dermatitis: A practical guideline. Pediatr Dermatol 2012, 29:24-27.
38. Song T. The efficacy of wet wrap treatment in children with atopic dermatitis. J Allergy Clin Immunol 2011, 127(2 suppl):AB36.